Table 3.

Adverse events in Cohort 2

Subjects	Concentration (one drop tid for 1 day; μg/ml)	Ocular AEs reported (no. of patients; severity)	Systemic AEs reported
6 rhNGF	20	Blurred vision (moderate) and pressure sensation (mild), left eye; increased fluorescein staining (mild–moderate), both eyes (n = 1)	None
6 rhNGF	60	None	None
6 rhNGF	180	Eye irritation (n = 1; mild); photophobia (n = 1; mild)	Ligament sprain (n = 1; severe)
6 placebo		Blurred vision (moderate, n = 1); eyelid irritation (moderate n = 1)	Headache (mild, n = 2); arthritis (mild, n = 1); depression (moderate, n = 1)

tid three times daily, AEs adverse events, rhNGF human recombinant nerve growth factor